Mankind Pharma is set to list on May 9 with a premium of Rs 120 apiece according to grey market trends. The company is valued at a price-to-earnings ratio of 30 times FY22 earnings and has a market capitalisation of Rs 44,000 crore. The initial share sale of the company was subscribed 15.32 times with strong interest from QIBs and is the largest IPO so far this year. The company has 25 manufacturing facilities across India, a dedicated in-house R&D centre and a team of over 600 scientists.
A break above 18600 could take Nifty to fresh highs: Kunal Shah
Analysts anticipate that bulls will regain control in the Indian equity markets once the Nifty index breaks above 18,600 on a closing basis. The breakthrough